Dosing regimen associated with long acting injectable paliperidone esters

Abstract

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

We claim: 
     
         1 .- 34 . (canceled) 
     
     
         35 . A dosing regimen for administering paliperidone palmitate to a renally impaired psychiatric patient in need of treatment for schizophrenia, schizoaffective disorder, or schizophreniform disorder comprising
 (a) administering intramuscularly in the deltoid of a renally impaired psychiatric patient in need of treatment a first loading dose of from about 100 mg-eq. of paliperidone as paliperidone palmitate formulated in a sustained release formulation on the first day of treatment; and   (b) administering intramuscularly in the deltoid muscle of the patient in need of treatment a second loading dose of from about 75 mg-eq. of paliperidone as paliperidone palmitate formulated in a sustained release formulation on the 6 th  to about 10th day of treatment.   
     
     
         36 . The dosing regimen of  claim 35  wherein after the second loading dose a first maintenance dose of about 25 mg-eq. to about 75 mg-eq. of paliperidone as paliperidone palmitate in a sustained release formulation is administered intramuscularly in the deltoid or gluteal muscle of the patient. 
     
     
         37 . The dosing regimen of  claim 36  wherein the first maintenance dose is administered a month (±7days) after the second loading dose. 
     
     
         38 . The dosing regimen of  claim 36  wherein the first maintenance dose is administered on between about the 34 th  and about the 38 th  day of treatment. 
     
     
         39 . The dosing regimen of  claim 36  wherein the first maintenance dose is 50 mg-eq. 
     
     
         40 . The dosing regimen of  claim 36  wherein after administration of the first maintenance dose, subsequent maintenance doses of from about 25 mg-eq. to 75 mg-eq. are administered in the deltoid or gluteal muscle of the psychiatric patient in need of treatment at monthly (±7 days) intervals. 
     
     
         41 . The dosing regimen of  claim 40  wherein the subsequent maintenance doses are 50 mg-eq. 
     
     
         42 . The dosing regimen of  claim 35  wherein the sustained release formulation is an aqueous nanoparticle suspension. 
     
     
         43 . The dosing regimen of  claim 42  wherein the nanoparticle suspension comprises:
 (a) from 3 to 20% (w/v) of the paliperidone palmitate having an average particle size (d50) of from about 1600 nm to about 900 nm; 
 (b) from 0.5 to 3% (w/v) of a wetting agent wherein the wetting agent is polysorbate 20; 
 (c) one or more buffering agents sufficient to render the composition neutral to very slightly basic (pH 8.5); 
 (d) from 0.5 to 3% (w/v) of a suspending agent wherein the suspending agent is polyethylene glycol 4000; and 
 (e) from 0%- 2% (w/v) preservatives; and 
 (f) water q.s. ad 100%. 
 
     
     
         44 . The dosage regimen of  claim 43  wherein the concentration of paliperidone palmitate is 156 mg/ml in the aqueous nanoparticle suspension. 
     
     
         45 . The dosing regimen of  claim 35  wherein the sustained release depot formulation is an aqueous nanoparticle suspension consists essentially of
 (a) 156 mg/ml of the paliperidone palmitate having an average particle size (d50) of from about 1600nm to about 900 nm; 
 (b) 12 mg/m1 of polysorbate 20; 
 (c) one or more buffering agents sufficient to render the composition neutral to very slightly basic (pH 8.5); 
 (d) 30 mg/ml of a suspending agent wherein the suspending agent is polyethylene glycol 4000; and 
 (e) water q.s. ad 100%. 
 
     
     
         46 . The dosage regimen of  claim 45  wherein in the buffering agents contained in the aqueous nanoparticle suspension are citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide. 
     
     
         47 . The dosage regimen of  claim 46  wherein in the pH of the aqueous nanoparticle suspension is in the range of pH 7 to 7.5. 
     
     
         48 . A dosing regimen for administering paliperidone palmitate to a psychiatric patient in need of treatment for schizophrenia, schizoaffective disorder, or schizophreniform disorder comprising
 (a) administering intramuscularly in the deltoid of a patient in need of treatment a first loading dose of about 150 mg-eq. of paliperidone as paliperidone palmitate formulated in a sustained release formulation on the first day of treatment; and   (b) administering intramuscularly in the deltoid muscle of the patient in need of treatment a second loading dose of about 100 mg-eq. of paliperidone as paliperidone palmitate formulated in a sustained release formulation on the 6 th  to about 10 th  day of treatment.   
     
     
         49 . The dosing regimen of  claim 48  wherein after the second loading dose a first maintenance dose of about 25 mg-eq. to about 150 mg-eq. of paliperidone as paliperidone palmitate in a sustained release formulation is administered intramuscularly in the deltoid or gluteal muscle of the patient. 
     
     
         50 . The dosing regimen of  claim 49  wherein the first maintenance dose is administered a month (±7 days) after the second loading dose. 
     
     
         51 . The dosing regimen of  claim 49  wherein the first maintenance dose is administered on between about the 34 th  and about the 38 th  day of treatment. 
     
     
         52 . The dosing regimen of  claim 49  wherein after administration of the first maintenance dose, subsequent maintenance doses of from about 25 mg-eq. to 150 mg-eq. are administered in the deltoid or gluteal muscle of the psychiatric patient in need of treatment at monthly (±7 days) intervals. 
     
     
         53 . The dosing regimen of  claim 48  wherein the sustained release formulation is an aqueous nanoparticle suspension. 
     
     
         54 . The dosing regimen of  claim 53  wherein the nanoparticle suspension comprises:
 (a) from 3 to 20% (w/v) of the paliperidone palmitate having an average particle size (d50) of from about 1600 nm to about 900 nm; 
 (b) from 0.5 to 3% (w/v) of a wetting agent wherein the wetting agent is polysorbate 20; 
 (c) one or more buffering agents sufficient to render the composition neutral to very slightly basic (pH 8.5); 
 (d) from 0.5 to 3% (w/v) of a suspending agent wherein the suspending agent is polyethylene glycol 4000; and 
 (e) from 0%-2% (w/v) preservatives; and 
 (f) water q.s. ad 100%. 
 
     
     
         55 . The dosage regimen of  claim 54  wherein the concentration of paliperidone palmitate is 156 mg/ml in the aqueous nanoparticle suspension. 
     
     
         56 . The dosing regimen of  claim 48  wherein the sustained release depot formulation is an aqueous nanoparticle suspension consists essentially of
 (a) 156 mg/ml of the paliperidone palmitate having an average particle size (d50) of from about 1600 nm to about 900 nm; 
 (b) 12 mg/ml of polysorbate 20; 
 (c) one or more buffering agents sufficient to render the composition neutral to very slightly basic (pH 8.5); 
 (d) 30 mg/ml of a suspending agent wherein the suspending agent is polyethylene glycol 4000; and 
 (e) water q.s. ad 100%. 
 
     
     
         57 . The dosage regimen of  claim 56  wherein in the buffering agents contained in the aqueous nanoparticle suspension are citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide. 
     
     
         58 . The dosage regimen of  claim 57  wherein in the pH of the aqueous nanoparticle suspension is in the range of pH 7 to 7.5.